Closures around the Strait of Hormuz create growing pharma supply chain risks. Find out how energy, API, and freight shocks spread and how to build resilience.
The closure of the Strait of Hormuz due to the U.S.-Iran conflict has turned a regional conflict into a pharmaceutical supply chain risk that reaches well beyond shipping.
Pharma needs to understand how energy, petrochemical, and logistics shocks travel through medicine production before shortages reach patients.
Image
Why Does the Strait of Hormuz Matter for Pharma Supply Chains?
The Strait of Hormuz links the Persian Gulf to the Gulf of Oman and the Indian Ocean. Most coverage focuses on oil and gas.
Yet the same waterway carries petrochemical feedstocks, and war effectively closed it in March 2026.
Pharmaceutical manufacturing depends on those feedstocks indirectly. A closed shipping lane raises freight costs, insurance premiums, and delivery times.
It can also disrupt the chemicals and energy that upstream suppliers need to keep producing.
To measure the true impact, a 2026 resilience analysis reviewed 22 peer-reviewed articles on maritime chokepoints. It found five recurring issues: Dependence on critical routes, the trade-off between efficiency and resilience, energy cost transmission, sustainability impacts, and the need for coordinated governance.
A medicine does not need to sit on a blocked ship to be affected. A delayed precursor, a costlier solvent, or a shortage of packaging material can halt production several tiers upstream.
The exposure sits across the whole network, not in a single shipping lane.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Image
How Does Conflict Disruption Reach Pharmaceutical Manufacturing?
Pharma combines global sourcing with strict rules on quality, traceability, and consistency.
A delayed input is therefore hard to replace quickly, even when another supplier looks available on paper.
Petrochemicals create indirect exposure
Petroleum and natural gas feed the production of solvents, reagents, polymers, and packaging components.
Energy-intensive chemical plants also face higher costs when fuel and electricity prices climb.
Not every active pharmaceutical ingredient (API) or medicine relies on materials that pass through the Strait. However, petrochemical price and supply shocks reach inputs made elsewhere, including in major manufacturing hubs.
Distance from the Gulf does not guarantee independence from it. A supplier on another continent may still depend on feedstocks, energy, or transport exposed to the same shock.
Antibiotics and generics face the sharpest risk
Writing in the British Journal of General Practice, Nejadghaderi and colleagues warn that the Strait carries feedstocks Indian manufacturers use to make APIs for generic medicines, including antibiotics.
India supplies about 47% of the generic medicines used in the US by volume. It also relies on the Strait for around 40% of its crude oil imports.
Air cargo from India can cost 200 to 350% more during a disruption. Inventories often cover only 30 to 60 days in many markets, so shortages can follow quickly.
Antibiotics carry extra risk. They are essential, high-volume products, and shortages can push clinicians towards broader-spectrum alternatives that may be less appropriate or more toxic.
Freight and energy costs compound
A maritime disruption triggers several costs at once.
Carriers reroute vessels, insurers reassess regional risk, and manufacturers pay more to move urgent consignments by other routes.
Longer journeys also make transit times harder to predict, which complicates inventory planning.
Air freight can speed up selected shipments, but its cost and capacity rule it out as a universal fix.
While lean supply chains save working capital in stable periods, they struggle when a critical route fails.
Supply teams should count the total cost of disruption, not just the ingredient price.
That total includes downtime, expedited freight, quality checks, regulatory work, and missed deliveries.
Image
Why Must Pharma Inventory and Supplier Strategies Change?
The instability around the Strait of Hormuz is a complete inventory, market, and communication issue.
Alongside logistics, resilience against geopolitical disruption should be managed as a standing planning task rather than a procurement emergency.
Stockpiling every material is neither practical nor affordable.
Pharmaceutical inputs carry expiry dates, storage conditions, and stability limits, and excess stock ties up working capital.
Manufacturers should instead segment materials by clinical importance, supplier concentration, replacement lead time, and disruption exposure.
Prioritise materials by risk, not price
A cheap excipient with one qualified source and a long replenishment cycle can stop a production line. An expensive material with several qualified suppliers may carry far less risk.
Teams should identify single-source dependencies, map upstream suppliers, and estimate how long qualifying an alternative would take.
Three measures give manufacturers a practical starting point:
Set risk-based inventory levels: Use lead times, supplier concentration, shelf life, clinical importance, and recovery time to size buffers.
Qualify alternatives early: Assess secondary suppliers, alternative routes, and substitute materials before a shortage forces rushed decisions.
These measures need shared ownership. Procurement sees commercial exposure, but quality assurance, regulatory affairs, manufacturing, supply planning, and finance decide what is feasible.
A new source has no value if it cannot meet specifications or enter the approved process without unacceptable disruption.
AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.
Image
From Reactive Procurement to Resilience Leadership
No organisation can eliminate geopolitical risk completely.
The aim is to spot emerging exposure sooner, understand its operational effects, and act without compromising medicine quality or patient access.
Build scenarios around disruption length
Model more than one outcome. A short interruption may need schedule changes and targeted inventory release. A prolonged one may demand alternative transport, revised production plans, supplier allocation decisions, and coordinated communication with health systems.
Each scenario needs defined triggers, such as sustained transit delays, supplier notices, route restrictions, price spikes, or falling stock cover.
Clear thresholds help teams act together instead of waiting for each department to reach its own conclusion.
Digital monitoring helps when it links supplier status, shipment tracking, inventory data, and market signals to specific decisions.
AI-assisted risk tools can spot patterns in large datasets. They should support expert judgement, not replace supplier verification or quality oversight.
Any change of material source or manufacturing site may need technical assessment and regulatory review.
Pharmatica’s Insights into CMC regulatory submissions and digital manufacturing shows how data quality and regulatory readiness shape a company's ability to manage change.
Make resilience a leadership responsibility
Supply continuity cannot sit with procurement alone. Teams need a cross-functional view of exposure, clear decision ownership, and agreed priorities when materials run short.
Teams should also check whether supplier continuity plans rely on the same vulnerable routes or upstream producers.
Policy matters too. Strategic stockpiles of critical antibiotics, more diversified API production, and supply resilience all sit within national antimicrobial resistance action plans.
Communication also counts. Unsupported reassurance damages trust, while late disclosure leaves distributors and healthcare providers little time to respond.
The goal is to shorten the time between recognising a disruption and taking quality-compliant action.
Strategic Takeaways for Pharma Supply Chain Teams
Supply chain issues from closure of the Strait of Hormuz shows how a regional security event can expose weaknesses in global medicine production.
Energy and petrochemical pressure, uncertain transport, and concentrated sourcing combine to threaten continuity, even for companies with no Gulf presence.
Resilience must be designed into sourcing, inventory, manufacturing, and supplier oversight.
Risk-based buffers, early-qualified alternatives, upstream visibility, and scenario-led decisions let companies respond without relying on emergency purchasing.
At Pharmatica, we examine the systems, strategies, and technologies shaping pharmaceutical manufacturing and supply continuity. Our Insights help decision-makers spot vulnerabilities earlier and make better-informed operational choices.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
How does the Strait of Hormuz closure affect pharmaceutical supply chains?
It raises energy, freight, and insurance costs and disrupts petrochemical feedstocks used to make solvents, reagents, and APIs. Effects reach manufacturers with no direct Gulf presence because the exposure sits several tiers upstream.
Why are antibiotics especially exposed to a Hormuz disruption?
Many generic antibiotics rely on APIs made in India from petrochemical inputs linked to Gulf trade. They are also essential, high-volume products, so shortages quickly affect treatment choices.
Which pharmaceutical materials carry the highest supply risk?
Materials with a single qualified source, a long replenishment cycle, and high clinical importance carry the most risk. Price alone is a poor guide.
Should pharma companies stockpile every material?
No. Expiry dates, storage needs, and working-capital costs make blanket stockpiling impractical. Risk-based buffers for critical materials work better.
What should pharma leaders do first?
Map critical APIs, starting materials, and packaging beyond first-tier suppliers. Then set inventory levels by risk and begin qualifying alternative sources.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
0
Why not support
Nicole Dale
by giving this content a like
Close the Drug Discovery Loop by Leveraging the DMTA Cycle
The DMTA cycle is the engine of modern pharma R&D. Learn how integrated DMTA workflows reduce early-stage attrition and compress drug discovery timelines.
Preclinical vs Clinical Research Strategy for Drug Development
Explore the critical differences between preclinical vs clinical research, and how closing the translation gap can reduce drug development attrition and improve R&D decision-making.
What 13 Years of Data Shows About Drug Innovation in Psychiatry
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Comments (0)